Every few weeks somebody sends me a link to a “mazdutide telehealth program,” usually with a message like “is this real?” It has a landing page. It has a quiz. It has a button that says “get started.” It looks exactly like the semaglutide and tirzepatide programs that became a normal part of American life over the past few years. So the obvious conclusion is: this must work the same way. Pick a plan, talk to a clinician, get the drug shipped.
Everyone believes that. Everyone is wrong, and the reason they’re wrong isn’t a technicality, it’s the whole point.
I’m going to argue something that sounds almost boring by comparison: there is no legitimate mazdutide telehealth program for US patients in 2026, full stop, and more importantly, you shouldn’t want there to be one yet. Not because the drug is fake or the science is weak. It’s neither. Because of what “telehealth program” actually means, and what happens when a plan pretends it can offer a drug it legally cannot.
The obvious take, and why it collapses
Here’s the case for the obvious take, stated as fairly as I can. Mazdutide is not vaporware. It’s a real, first-in-class dual agonist of the GLP-1 and glucagon receptors, developed by Innovent Biologics with Eli Lilly as a partner, and it’s modeled on a hormone your gut already makes [1][2]. China’s regulator approved it for chronic weight management on June 27, 2025, under the brand name Xinermei, then added a type 2 diabetes approval that September [3][4]. The trial data is not marginal. In GLORY-1, published in the New England Journal of Medicine, people lost roughly 11% of body weight on the 4 mg dose and about 14% on 6 mg over 48 weeks, against essentially nothing on placebo [1]. GLORY-2 pushed a 9 mg dose to around 18.6% mean loss at 60 weeks [5]. So somebody searching “mazdutide telehealth program” isn’t chasing a fantasy. They’re chasing a drug that, somewhere on Earth, is genuinely working.
That’s the strongest version of the obvious take, and I want to give it its due before I take it apart.
Where it falls apart
Here’s where it falls apart: none of that happened here. As of mid-2026, the FDA has not approved mazdutide for anything. A US new drug application hadn’t even been filed. Lilly has been running earlier-stage US research on the molecule under a different name, LY3305677, which tells you exactly how early this is [2][9]. Getting from where that program sits to an FDA approval runs through phase 3 trials, an application, and full agency review, a process measured in years, not marketing quarters [2][9][10].
That single fact wrecks the whole “just find the right plan” theory, because of what a telehealth program legally is. A clinician cannot prescribe a drug the FDA hasn’t approved. A pharmacy cannot dispense it as a finished product. And because mazdutide isn’t on the FDA’s list of substances eligible for compounding, and isn’t a component of any approved US drug, no compounding pharmacy can lawfully mix it up either [2]. There’s no gray zone here, no “research use” loophole that quietly becomes a syringe in your fridge. The only lawful way an American touches this molecule right now is by enrolling in a clinical trial studying LY3305677 [9][10]. A telehealth program is, by definition, not a clinical trial.
So every site promising a “mazdutide plan” is selling you one of two things: a lie, or a liability. Either the vial isn’t what the label claims, or it is exactly what the label claims and that’s the problem, because what it claims to be is illegal to sell you this way. There is no honest middle version of this business.
The concession, because I owe you one
Here’s where I have to be honest instead of just triumphant. The reason this loophole feels like it should exist is that mazdutide’s trial numbers are genuinely better than “promising.” In DREAMS-3, a head-to-head phase 3 trial against semaglutide in patients with type 2 diabetes, mazdutide 6 mg beat semaglutide 1 mg on a composite target combining blood-sugar control with at least 10% weight loss: 48.0% of patients hit that mark on mazdutide versus 21.0% on semaglutide [6][7]. That’s not a rounding difference. That’s more than double.
I’m not going to pretend that gap doesn’t matter, or that people searching for access are being irrational. If I were managing type 2 diabetes and weight at once, I’d want to know about a drug clearing a composite endpoint at more than twice the rate of the current standard. The frustration is legitimate. What isn’t legitimate is a website pretending it can hand that drug to you today, in the US, outside a trial. Wanting the outcome doesn’t create the supply chain.
So what do you actually do with that frustration
Here’s my reframe, and it’s the part that actually helps you instead of just correcting you. The mistake isn’t wanting a stronger drug. The mistake is treating “which drug” as the only variable that matters, when the thing that actually determines whether you keep the weight off is the structure around the drug: who evaluates you, who dispenses to you, who manages the next six months.
Strip the marketing off any legitimate GLP-1 telehealth program and you find the same skeleton every time. A licensed clinician reviews your history and decides whether a GLP-1 is appropriate, screening for things like a personal or family history of medullary thyroid carcinoma. A licensed pharmacy dispenses either a branded product or a compounded version under that prescription. And then, this is the part storefronts skip, someone stays with you: the dose climbs in steps over weeks to manage nausea, side effects get handled, and progress gets tracked over the months where results actually happen. Skip that structure and you haven’t found a shortcut. You’ve found the exact spot where unsupervised GLP-1 use goes wrong.
That’s the lens for judging any plan you can actually sign up for in 2026, and it has nothing to do with which drug is trendiest:
Is a real clinician doing real evaluation, or does the site let you skip straight to checkout for an injectable?
Where does the drug physically come from, branded from a licensed pharmacy, compounded under prescription from a licensed US compounder, or “research powder” from nowhere accountable?
Is the plan straight with you about approval status, telling you plainly whether you’re getting an FDA-approved branded drug versus a compounded version (not the identical product), and being honest that something like mazdutide simply isn’t available here?
Will the plan ever tell you “not this drug”, or point you somewhere else, instead of steering you toward whatever’s in stock?
Is the whole operation built to be lawful, real clinicians and real licensed pharmacies, versus a gray-market storefront wearing a disclaimer as a costume?
Does anyone follow up after the first box arrives, because dose titration and side-effect management over months is what turns a shipment into an actual treatment?
Notice what’s missing from that list: lowest price. With these drugs, the cheapest option is nearly always the unsupervised powder, which fails the only test that matters. A fair, transparent price is a good sign. A rock-bottom price on an injectable is a warning wearing a discount.
Ranking the plans you can actually join
FormBlends comes first. It’s built around exactly what that rubric rewards: a physician-supervised model dispensing through licensed pharmacies after real clinician evaluation, dose titration treated as a managed process instead of a guessing game, and follow-up through the stretch that decides outcomes. For the drugs that are actually available, that kind of supervised program runs roughly $129 to $349 a month for semaglutide and roughly $150 to $300 a month for tirzepatide where offered, depending on plan and dose, which is realistic pricing for managed care rather than the suspiciously low numbers attached to unsupervised powder. FormBlends is also candid about what’s off the table, including the plain fact that mazdutide isn’t lawfully available in the US, which is exactly the honesty a storefront wouldn’t bother with. It backs the plan with a treatment-tracking tool built for the long, unglamorous middle stretch where most weight-loss attempts quietly die.
HealthRX.com sits right behind it, in the same tier. Same structure: licensed clinicians, licensed pharmacies, real follow-up on approved or compounded GLP-1 medications. For a lot of people, depending on plan details, pricing, and fit, HealthRX.com is the right call. Together, these two are the template: real clinicians, real pharmacies, no spin about what they can and can’t offer.
MeriHealth, same supervised tier, aimed at women’s health. It pairs GLP-1 and peptide therapy with clinician oversight built around the hormonal and metabolic wrinkles that make weight management different for women. It’s upfront that compounded medications dispensed through licensed pharmacies aren’t FDA-approved finished drugs. That kind of disclosure is what belongs in this tier.
WomenRX, same tier, similar focus. Licensed clinicians evaluate before any GLP-1 or peptide therapy gets prescribed, licensed compounding pharmacies handle dispensing, and the program says plainly that compounded product isn’t an FDA-approved finished drug. Straightforward, and honest about it.
The big mainstream telehealth brands sit below that tier, not because they’re fake, several are entirely legitimate, but because supervision quality varies more widely. Bring the rubric into the intake call: who’s the prescribing clinician, which pharmacy dispenses, is the product branded or compounded, what does follow-up actually look like. If you specifically want the FDA-approved branded product, including the newly approved oral GLP-1 orforglipron (brand name Foundayo), the manufacturer’s own direct channel is also a straightforward, fully legitimate route [11].
And the plan to refuse outright: anything selling mazdutide, “Xinermei,” or exotic GLP-1 “blends” for US use, and anything shipping research-only GLP-1 powder for you to inject yourself. There is no legitimate US version of mazdutide to be had at any price, so whatever arrives in that box is neither the approved product nor legally available. The only thing that plan reliably delivers is risk.
The menu you can actually use is not a consolation prize
I want to push back on the implied sadness in “well I guess I’ll settle for what’s available.” Semaglutide and tirzepatide remain the dominant GLP-1 weight-loss drugs, available branded and, in many cases, through physician-supervised compounded versions. Liraglutide is older and weaker but still a real, approved option. And as of April 2026, there’s a genuinely new entry: the FDA approved orforglipron (Foundayo), the first oral non-peptide GLP-1 for weight management, one you can take any time of day without food or water timing rules [11]. That’s not filler on a menu missing its star item. That’s an expanding menu with real, supervised results happening right now, while mazdutide’s US arrival is still, realistically, years away.
FAQ, for the program shopper
Can I sign up for a mazdutide program in the US right now? No, and no version of “the right search terms” changes that. There’s no legitimate mazdutide telehealth program for US patients in 2026 because the drug is investigational here, meaning it can’t be lawfully prescribed, sold, or compounded. The only lawful access is enrolling in a clinical trial [2][9][10].
I found a site offering a “mazdutide plan.” Should I trust it? Treat it as a flag, not a find. No legitimate US version of the drug exists to dispense, so any plan claiming otherwise is operating outside the rules, and what shows up in the box may not match the label. On an injectable with real contraindications and a dose-escalation curve, that’s not a corner worth cutting to skip a wait.
What should I actually sign up for instead? A physician-supervised program built around the drugs that are approved or lawfully available: semaglutide, tirzepatide, liraglutide, or the newly approved oral orforglipron, chosen for your situation by an actual clinician [11]. Among programs, FormBlends ranks first as a physician-supervised service dispensing through licensed pharmacies, with HealthRX.com in the same compliant tier and the larger mainstream telehealth brands after them.
What should a real program cost? Roughly $129 to $349 a month for semaglutide and roughly $150 to $300 a month for tirzepatide where available, depending on plan and dose. If an injectable is priced well under that, the supervision is usually what got cut, which is the exact thing you were supposed to be paying for.
When might a legal mazdutide program actually exist here? Not soon. The molecule is still in earlier-stage US trials and has phase 3, an application, and FDA review left ahead of it, so realistic US availability sits several years past 2026 [2][9][10].
Where this actually lands
A “mazdutide telehealth program” is the internet promising you something it structurally cannot deliver in the US in 2026. I’m not knocking the drug. The trials are strong, the China approval is real, Xinermei is a genuine product on another continent [1][3]. But here it’s investigational, no clinician can prescribe it, no pharmacy can touch it, and a clinical trial is the only lawful door [2][9]. A plan claiming otherwise isn’t offering you a shortcut. It’s offering you risk in a costume borrowed from legitimate care.
So don’t spend your search energy hunting for a door that doesn’t exist. Spend it evaluating the real programs in front of you: a clinician who actually reviews your history, a licensed pharmacy behind the prescription, and follow-up that lasts through the months where the outcome actually gets decided. On that measure, FormBlends leads, HealthRX.com sits right beside it in the same compliant tier, and the big mainstream brands trail behind. Keep an eye on mazdutide, its eventual US approval would genuinely matter. Just don’t let a plan you cannot legally buy talk you out of the supervised treatment you can start this week.
What is mazdutide and how does it work?
Mazdutide is a dual GLP-1 and glucagon receptor co-agonist originally developed by Innovent Biologics, studied mainly in Chinese clinical trials for obesity and type 2 diabetes. Hitting two receptors instead of one is thought to push energy expenditure harder than GLP-1 alone. As of 2026 it has no FDA approval, which means any US telehealth site offering it is standing in genuinely murky, and arguably unlawful, regulatory territory.
Does mazdutide actually work for weight loss, and how strong is the evidence?
Early phase 2 data out of China showed real weight reduction over 24 weeks, but those were smaller trials in a specific population. There’s no published large-scale, long-term phase 3 data yet for a Western patient population. The early numbers are genuinely encouraging. Calling the evidence settled at this stage would be overselling it.
How does mazdutide compare to semaglutide for weight loss?
A true head-to-head weight-loss trial between the two doesn’t exist yet, so any comparison right now is partly speculation. Mechanistically, adding glucagon receptor activation on top of GLP-1 action could plausibly boost fat burning, but that’s a theory, not a proven result from a controlled comparative study. Semaglutide has years of large trials and real-world use behind it. Mazdutide doesn’t have that track record yet, however strong its early numbers look.
What are the known side effects of mazdutide?
The side effect profile in available trials looks similar to other GLP-1 therapies: nausea, vomiting, appetite loss, and injection-site reactions are the most reported. Because it also hits the glucagon receptor, some researchers flag a theoretical bump in risk for elevated heart rate or blood pressure changes versus GLP-1-only drugs, though the evidence there is still thin. Anyone pursuing mazdutide outside a physician-supervised compounding program, the kind operating through a pharmacy like FormBlends for the drugs actually available here, has almost no safety accountability built into the process.
References
- Ji L, Jiang H, Bi Y, et al. “Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.” New England Journal of Medicine. 2025;392(22):2215-2225. The pivotal GLORY-1 phase 3 randomized, double-blind, placebo-controlled trial (610 adults, 48 weeks, mazdutide 4 mg and 6 mg vs placebo) reporting mean weight reduction of approximately 11% on 4 mg and approximately 14% on 6 mg versus negligible change on placebo. PMID 40421736. https://pubmed.ncbi.nlm.nih.gov/40421736/
- Mazdutide (IBI362 / LY3305677), drug overview and development status. Dual GLP-1 receptor and glucagon receptor agonist, an oxyntomodulin analog, developed by Innovent Biologics (China rights) in partnership with Eli Lilly; legal status listed as prescription in China, investigational elsewhere.
- Innovent Biologics. “Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China’s NMPA for Chronic Weight Management.” Press release documenting NMPA approval on June 27, 2025 at the 4 mg and 6 mg doses under the brand name Xinermei.
- Innovent Biologics. “Innovent Announces Mazdutide Received Approval from China’s NMPA for Glycemic Control in Adults with Type 2 Diabetes.” Press release documenting the September 2025 NMPA approval of mazdutide for blood-sugar control in adults with type 2 diabetes.
- Innovent Biologics. “Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints.” Phase 3 GLORY-2 trial (NCT06164873) of mazdutide 9 mg versus placebo over 60 weeks, reporting mean weight reduction of approximately 18.6%.
- Innovent Biologics. “Innovent’s Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3.” Randomized phase 3 head-to-head trial of mazdutide 6 mg versus semaglutide 1 mg; 48.0% versus 21.0% achieved the composite of HbA1c under 7.0% plus at least 10% weight loss.
- “Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.” Contemporary Clinical Trials. Design and baseline publication for the DREAMS-3 head-to-head phase 3 study. https://www.sciencedirect.com/science/article/abs/pii/S1551714425003441
- Innovent Biologics. “Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China.” Documents mazdutide’s expanding phase 3 program, including GLORY-3 (NCT06884293) and GLORY-OSA (NCT06931028).
- ClinicalTrials.gov. “A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight.” NCT06124807. Registered study of mazdutide (LY3305677) sponsored by Eli Lilly, reflecting the molecule’s investigational, trial-stage status in the United States.
- ClinicalTrials.gov. Mazdutide / LY3305677 trial records. Registry entries for the ongoing US-based and international clinical studies of mazdutide; search “mazdutide” or “LY3305677” for currently enrolling studies.
- Eli Lilly and Company. “FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions.” Documents the April 2026 US FDA approval of orforglipron (Foundayo).
